Abstract

Chronic kidney disease (CKD) carries an increased risk of cardiovascular disease (CVD). Macrophage migration inhibiting factor (MIF) is a proinflammatory cytokine implicated in the pathogenesis of sepsis, autoimmune disease, atherogenesis, and plaque instability, and is a known cardiac depressant. This post-hoc, cross-sectional study examined whether MIF serum concentrations are elevated in CKD patients. Our study included CKD 3-5 patients with moderate to severe renal dysfunction (n = 257) (mean age SD; 55 +/- 12 years) and 53 controls (60 +/- 12 years). Serum MIF concentrations, measured by enzyme-linked immunosorbent assay (ELISA), were studied in relation to glomerular filtration rate (GFR), presence of CVD, outcome and inflammatory and oxidative stress markers. MIF was significantly elevated in CKD patients compared with controls (CKD: median 676 [range 118-8275 pg/mL] controls: 433 [142-4707] pg/mL; P = 0.008). MIF was also associated with 8-hydroxy-2-deoxyguanosine (8-OH-dG) levels (rho = 0.26; P = 0.001), a marker of oxidative stress, and ICAM-1 levels (rho = 0.14; P = 0.02), a marker of endothelial activation. However, the elevated MIF concentrations were neither correlated with glomerular filtration rate (GFR) nor inflammatory markers such as CRP, IL-6, and TNF. When combining MIF and IL-6 as a marker of inflammation, a significant increase in risk for CVD was found, but when analyzing all-cause mortality, this did not differ significantly with regard to mortality from inflamed patients with low MIF levels. The data suggest that increased serum MIF levels found in CKD is not caused primarily by poor renal function, but is associated with markers of oxidative stress and endothelial activation and may play a role in vascular disease associated with CKD.

Highlights

  • Chronic inflammation, measured with biomarkers such as interleukin-6 (IL-6), neutrophils, and C-reactive protein (CRP), has been the focus of numerous studies in chronic kidney disease (CKD)

  • There were no differences in migration inhibitory factor (MIF) levels among patients with or without clinical cardiovascular disease, diabetes mellitus, gender, or protein-energy wasting as assessed by SGA (Subjective Global Assessment)—data not shown

  • Univariate and Multivariate Correlates for MIF Levels

Read more

Summary

Introduction

Chronic inflammation, measured with biomarkers such as interleukin-6 (IL-6), neutrophils, and C-reactive protein (CRP), has been the focus of numerous studies in chronic kidney disease (CKD). These inflammatory markers have been found to be predictors of all-cause and cardiovascular mortality independent of traditional risk factors for cardiovascular disease (CVD) and are associated with atherosclerotic cardiovascular disease [1,2,3,4]. One study reported increased circulating MIF levels in vasculitis patients and another study examined MIF in the urine of transplanted patients [14,15] These studies were small and did not control for the influence of renal function. The aim of this current study was, to determine whether circulating MIF levels were elevated in CKD 3–5 patients with a wide range of GFR

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call